Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where ,Health for all, Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Location: Basel, Switzerland • Hybrid 3 days/week in office Internal job title: Associate Director, Agentic AI Solutions Product Manager About the Role We are seeking a Product Manager Agentic AI Solutions to lead the product strategy,
In this role, you hold overall responsibility for information security across the organization. You continuously develop the information‑security strategy, the Information Security Management System (ISMS) , and the internal control system (ICS) . You lead IT
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Overview We are seeking an exceptional and highly motivated Postdoctoral Researcher to lead research on multimodal reasoning models for oncology. The project focuses on developing, post-training, and evaluating flexible AI models that can support complex oncologic
We are seeking an exceptional and highly motivated Postdoctoral Researcher to lead research on multimodal reasoning models for oncology. The project focuses on developing, post-training, and evaluating flexible AI models that can support complex oncologic diagnostic
Postdoctoral Researcher in Multimodal Reasoning Models for Oncology We are seeking an exceptional and highly motivated Postdoctoral Researcher to lead research on multimodal reasoning models for oncology. The project focuses on developing, post‑training, and evaluating flexible
Postdoctoral Researcher in Multimodal Reasoning Models for Oncology We are seeking an exceptional and highly motivated Postdoctoral Researcher to lead research on multimodal reasoning models for oncology. The project focuses on developing, post-training, and evaluating flexible